Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 101: sotorasib with panitumumab with or without chemotherapy in KRAS G12C-mutant advanced solid tumors
jRCT2031210121Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of sotorasib and panitumumab in Nonhematologic neoplasms and colorectal cancer (CRC), sponsored by Amgen. Primary endpoints: Number of participants with dose-limiting toxicities, Number of participants with treatment-emergent adverse events and 4 more. Started Dec 2019; status: active, not recruiting.
02
Drugs
sotorasibpanitumumab
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031210121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210121.